Nature Communications (May 2021)
Development of selective bispecific Wnt mimetics for bone loss and repair
- Tristan W. Fowler,
- Troy L. Mitchell,
- Claudia Y. Janda,
- Liqin Xie,
- Shengjiang Tu,
- Hui Chen,
- Haili Zhang,
- Jingjing Ye,
- Brian Ouyang,
- Tom Z. Yuan,
- Sung-Jin Lee,
- Maureen Newman,
- Nikita Tripuraneni,
- Erica S. Rego,
- Devin Mutha,
- Archana Dilip,
- Meghah Vuppalapaty,
- Helene Baribault,
- Wen-Chen Yeh,
- Yang Li
Affiliations
- Tristan W. Fowler
- Surrozen, Inc.
- Troy L. Mitchell
- Surrozen, Inc.
- Claudia Y. Janda
- Surrozen, Inc.
- Liqin Xie
- Surrozen, Inc.
- Shengjiang Tu
- Surrozen, Inc.
- Hui Chen
- Surrozen, Inc.
- Haili Zhang
- Surrozen, Inc.
- Jingjing Ye
- Surrozen, Inc.
- Brian Ouyang
- Surrozen, Inc.
- Tom Z. Yuan
- Surrozen, Inc.
- Sung-Jin Lee
- Surrozen, Inc.
- Maureen Newman
- Surrozen, Inc.
- Nikita Tripuraneni
- Surrozen, Inc.
- Erica S. Rego
- Surrozen, Inc.
- Devin Mutha
- Surrozen, Inc.
- Archana Dilip
- Surrozen, Inc.
- Meghah Vuppalapaty
- Surrozen, Inc.
- Helene Baribault
- Surrozen, Inc.
- Wen-Chen Yeh
- Surrozen, Inc.
- Yang Li
- Surrozen, Inc.
- DOI
- https://doi.org/10.1038/s41467-021-23374-8
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 13
Abstract
Antibody-based Wnt agonists are able to phenocopy Wnt signaling in vivo resulting in increased bone density, repair, and strength. Here, the authors show that Wnt agonists can reverse bone loss associated with ovariectomy and build stronger bone when administered after fracture.
